These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8420190)
1. Parkinson's disease before age 30. Lima AB; Levy A; Caldas AC; Neves G; Lopes G; Sampaio C Adv Neurol; 1993; 60():553-7. PubMed ID: 8420190 [No Abstract] [Full Text] [Related]
2. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206 [No Abstract] [Full Text] [Related]
4. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Merello M; Nouzeilles MI; Arce GP; Leiguarda R Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878 [TBL] [Abstract][Full Text] [Related]
5. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Pantelatos A; Fornadi F Adv Neurol; 1993; 60():690-7. PubMed ID: 8420212 [TBL] [Abstract][Full Text] [Related]
6. CSF biopterin levels and clinical features of patients with juvenile parkinsonism. Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H Adv Neurol; 1993; 60():562-7. PubMed ID: 8420192 [No Abstract] [Full Text] [Related]
7. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Greene P; Cote L; Fahn S Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214 [No Abstract] [Full Text] [Related]
9. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. McColl CD; Reardon KA; Shiff M; Kempster PA Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061 [TBL] [Abstract][Full Text] [Related]
10. Apomorphine test for dopaminergic responsiveness: a dose assessment study. Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482 [TBL] [Abstract][Full Text] [Related]
15. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease. Lieberman AN; Gopinathan G; Pasternack P; Goldstein M Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521 [No Abstract] [Full Text] [Related]
16. Protective effect of selegiline in the early and late phases of Parkinson's disease. Csanda E; Tárczy M Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208 [No Abstract] [Full Text] [Related]
17. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome. Yokochi M Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189 [No Abstract] [Full Text] [Related]
18. Parkinson's disease. Clarke C; Moore A Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943 [No Abstract] [Full Text] [Related]
19. [Levodopa dependency in Parkinson's disease: case report and review]. Müller U; Reuter M; Hermann W; Gertz HJ Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883 [TBL] [Abstract][Full Text] [Related]
20. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus). Fischer PA Adv Neurol; 1987; 45():235-8. PubMed ID: 3825695 [No Abstract] [Full Text] [Related] [Next] [New Search]